Special Protocol Assessment For Navidea’s Parkinson’s Diagnostic Could Help With Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects to have data to support reimbursement of its radiopharmaceutical diagnostic NAV5001 and avoid the Medicare coverage struggles encountered by Lilly’s Amyvid; SPA reached with FDA encompasses two Phase III trials with 550 total patients.